Trevor James
The US Food and Drug Administration (FDA) has indicated that it may not renew the emergency use authorization (EUA) for Pfizer's COVID-19 vaccine for children aged 6 months to 4 years old. This decision could potentially limit the availability of vaccines for young children, as Pfizer's vaccine is currently the only COVID-19 vaccine approved for all children in the US market. While the FDA has not provided specific reasons for its potential decision, it has been speculated that the low uptake of the vaccine and changes in US COVID vaccine policy may have influenced this development. Meanwhile, the FDA has granted full approval to Moderna's COVID-19 vaccine for children aged 6 months to 11 years old with underlying conditions, providing another option for pediatric vaccination.
| Characteristics | Values |
|---|---|
| Date of search | 22 August 2025 |
| FDA approval of Pfizer vaccine for young children | May not be renewed in the fall of 2025 |
| FDA approval of Moderna vaccine for young children | Approved in July 2025 for children aged 6 months to 11 years with underlying conditions |
| Novavax vaccine approval for young children | Approved for children aged 12 and up with health conditions |
| Percentage of children vaccinated against Covid | 5.6% of children aged 6 months to 4 years; about 15% of children aged 5 to 17 |
| Covid hospitalization rates for children | Similar to rates in 2020 and 2021 |
| Covid long-term impact on children | Can cause a multisystemic inflammatory process; long-term implications for long Covid in kids are unknown |
| Covid vaccine recommendation for healthy children | Removed by Health and Human Services Secretary Robert F. Kennedy Jr. in May 2025 |
Explore related products
What You'll Learn
The FDA may not renew Pfizer's emergency use authorization for kids
As of August 2025, the US Food and Drug Administration (FDA) is considering whether to renew the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine for children aged 6 months to 4 years. If the FDA chooses not to renew the EUA, it would leave a gap in vaccine availability for young children in the US.
Pfizer first received the EUA for its COVID-19 vaccine for young children in June 2022. However, uptake has been low, with only 5.6% of children aged 6 months to 4 years vaccinated against COVID-19, according to the CDC. The FDA's potential decision not to renew the EUA is based on the expiration of the federal public health emergency in May 2023, which ended the COVID-19 pandemic.
The FDA's move would pull the only remaining COVID-19 vaccine for all children under five from the US market. While Moderna's pediatric vaccine is FDA-approved, it is only available for children with one or more health conditions. Similarly, Novavax's protein-based COVID-19 vaccine is cleared for use in people aged 12 and older. This leaves limited options for vaccinating young children in the US.
The FDA's potential decision has sparked concern among parents, caregivers, and pediatricians, who are awaiting further updates from the FDA and CDC. Alternative planning may be needed, especially for healthy children outside of Moderna's restricted approval. Pfizer is currently in talks with the FDA to find a path forward for its pediatric vaccine and has asked that the EUA in kids under 5 years old stays in place for the 2025-26 season.
Robert Kennedy Jr.'s Anti-Vaccine Claims: A Discussion
You may want to see also
Explore related products
$11.93 $21.99
The Moderna vaccine is FDA-approved for kids with underlying conditions
In July 2025, the US Food and Drug Administration (FDA) approved Moderna's Covid-19 vaccine for children aged 6 months to 11 years old. This approval, however, comes with a stipulation—the vaccine is only authorized for children with one or more underlying health conditions that put them at increased risk for severe Covid-19 disease.
The FDA's decision was influenced by the statement that healthy children infected with Covid-19 have "consistently shown strong resilience and face an extremely low risk of serious illness or harm." As a result, the risks of potential side effects from the vaccine may outweigh the benefits for healthy children. The Department of Health and Human Services (HHS) spokesperson, Andrew Nixon, emphasized that "all families retain the option to consult with their child's physician about whether to receive the Covid-19 vaccine."
The Moderna vaccine's approval for at-risk children is significant as it provides an important tool for protecting young individuals against severe disease and hospitalization from Covid-19. Stéphane Bancel, chief executive officer of Moderna, affirmed that "Covid-19 continues to pose a significant potential threat to children, especially those with underlying medical conditions."
It's worth noting that the FDA's approval of the Moderna vaccine for children with underlying conditions comes amidst uncertainty surrounding the authorization of the Pfizer vaccine for young children. Reports suggest that the FDA may not renew the emergency use authorization (EUA) for Pfizer's Covid-19 vaccine for children under the age of 5, which has been available under EUA since June 2022. This decision could potentially limit the availability of Covid-19 vaccines for healthy young children, as the Pfizer vaccine is currently the only one approved for this age group.
The evolving landscape of Covid-19 vaccine approvals and recommendations underscores the importance of staying informed and consulting with healthcare professionals when making decisions regarding vaccinations for children.
Vaccines Without Abortion: Is It Possible?
You may want to see also
Explore related products
Novavax is the only non-mRNA COVID-19 shot approved for kids
The US Food and Drug Administration (FDA) has indicated that it may not renew the emergency use authorization (EUA) for Pfizer's COVID-19 vaccine for children aged 6 months to 4 years. This decision could potentially limit vaccine options for young children, as the Moderna vaccine, which is the only other vaccine approved for this age group, is only accessible to children with one or more health conditions.
The Novavax COVID-19 vaccine has been approved by the FDA for individuals 12 years of age and older with at least one high-risk health condition. It is the only protein-based COVID-19 vaccine available in the US and is distinct from the mRNA vaccines developed by Pfizer and Moderna. Novavax's vaccine was initially authorized for emergency use in individuals aged 12 and above, and its approval for high-risk groups was granted following a review of data from a 30,000-person clinical trial that demonstrated the vaccine's safety and efficacy.
While the FDA has not provided specific reasons for restricting Novavax's vaccine to specific groups, this decision aligns with the views of US Health Secretary Robert F. Kennedy Jr., who has previously expressed skepticism toward vaccination. Novavax's CEO, John Jacobs, emphasized the significance of this approval for high-risk populations.
The limited availability of vaccines for young children has raised concerns among public health experts, who note that even otherwise healthy children under 2 are still vulnerable to COVID-19. While the rates of hospitalization and death are highest among older adults, children continue to experience hospitalization rates from COVID-19 similar to those seen in 2020 and 2021.
The potential impact of COVID-19 on children's long-term health is also a cause for concern. The disease can trigger a multi-systemic inflammatory process in some children, and the long-term consequences of long COVID in kids are still unknown. As of August 2025, the FDA has not renewed Pfizer's COVID-19 vaccine for young children, and Moderna is working to increase its vaccine supply for this age group.
How Aminoglycosides Enhance Vaccine Efficacy
You may want to see also
Explore related products
The FDA removed the COVID-19 vaccine recommendation for healthy kids
The US Food and Drug Administration (FDA) is considering removing the COVID-19 vaccine recommendation for healthy children under the age of five. This move would leave parents of healthy children with no vaccine options. Currently, the Moderna vaccine is only approved for children with one or more health conditions, and the Novavax vaccine is only available for children aged 12 and up with health conditions. The Pfizer vaccine is the only vaccine available for healthy children, and its authorization may not be renewed by the FDA.
The FDA's potential decision to remove the COVID-19 vaccine recommendation for healthy children is based on the low uptake of the vaccine in this age group. According to the CDC, only 5.6% of children aged six months to four years are vaccinated against COVID-19. However, public health experts argue that the coronavirus is still a threat to healthy children under two. During the winter rise in cases last year, emergency department visits were elevated for young children.
The FDA's anticipated narrowing of COVID-19 vaccine eligibility will create new hurdles for Americans seeking to get vaccinated. The authority of pharmacists to vaccinate individuals varies across state lines, and some healthy individuals may need to prove they have an underlying condition or get a prescription to receive a vaccine. This may cause some people to skip the vaccine or seek an off-label prescription from a doctor, which pharmacists may be reluctant to provide.
The FDA's decision to remove the COVID-19 vaccine recommendation for healthy pregnant women in May caused controversy, and the potential removal of the recommendation for healthy children has sparked similar concerns. The CDC later reinstated the recommendation for healthy pregnant women, allowing vaccinations through shared decision-making between families and providers. It remains to be seen what the exact implications of the FDA's potential decision to remove the COVID-19 vaccine recommendation for healthy children will be.
Protecting Healthy Cells: Blocking Viral Entry and Attack
You may want to see also
Explore related products
Low vaccination rates among kids
Low vaccination rates among children have been a cause for concern, with potential impacts on public health and the ongoing pandemic. As of 2025, only about 5.6% of children aged six months to four years are vaccinated against COVID-19, and approximately 15% of those aged five to 17 have received their shots. This is in stark contrast to older adults, who have significantly higher vaccination rates, albeit with higher hospitalization and death rates from the virus.
There are several factors contributing to the low vaccination rates among children. Firstly, there has been a lack of promotion and education regarding vaccinations for kids. This has been exacerbated by unscientific statements and skepticism about the safety and efficacy of vaccines, particularly COVID-19 vaccines, by prominent figures such as Robert F. Kennedy Jr. Kennedy's stance against pediatric vaccinations has led to a feud with American doctors and pediatricians' groups, creating confusion and distrust among parents and caregivers.
Additionally, changes in US COVID-19 vaccine policy have impacted the availability and accessibility of vaccines for children. The removal of the COVID-19 vaccine recommendation for healthy children by the CDC and the potential decision by the FDA to not renew the authorization of the Pfizer vaccine for young kids could further limit vaccine options for this age group.
The low vaccination rates have implications for public health and the ongoing pandemic. Children continue to be affected by COVID-19, with hospitalization rates similar to those in 2020 and 2021. The long-term impacts of COVID-19 on children are still unknown, and the disease can cause a multisystemic inflammatory process in some kids, with potential severe consequences.
Furthermore, low vaccination rates among children can have broader implications for community health. For example, measles vaccination rates have declined since the peak in the 2019-2020 school year, dropping from 95.2% to 92.5%. While this majority of children entering kindergarten are still vaccinated, it falls short of the 92-95% rate required to achieve "herd immunity," which protects even the unvaccinated members of a community.
To address these challenges, healthcare providers and public health organizations must work to educate parents and caregivers about the safety and importance of vaccinating their children. Additionally, ensuring the availability and accessibility of vaccines, as well as clear and consistent messaging from health authorities, can help improve vaccination rates among kids.
US Entry Rules: Vaccines and Immigrants
You may want to see also
Frequently asked questions
No, the FDA did not approve the Pfizer Covid-19 vaccine for young children. In fact, in 2025, the FDA signalled that it might not renew the emergency use authorisation for Pfizer's vaccine for children aged 6 months to 4 years old.
Yes, the FDA approved Moderna's Covid-19 vaccine for children aged 6 months to 11 years old in July 2025. However, this vaccine is only available for children with at least one underlying condition that puts them at high risk for severe Covid-19 outcomes.
The FDA's decision to not renew Pfizer's emergency use authorisation would remove the only Covid-19 vaccine approved for all children from the US market. This could create a hole in the availability of vaccines for the youngest kids.
While older adults have the highest rates of hospitalisation and death, children continue to see hospitalisation rates from Covid-19 similar to rates in 2020 and 2021. There are concerns about the long-term impact of Covid-19 on children, as it can cause a multi-systemic inflammatory process with unknown long-term implications.
